Salehi Mehrdad, Emadossadat Alireza, Kheirabadi Gholam Reza, Maracy Mohammad Reza, Sharbafchi Mohammad Reza
From the *Department of Psychiatry, School of Medicine, †Behavioral Sciences Research Center, School of Medicine, and Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.
J Clin Psychopharmacol. 2015 Dec;35(6):724-7. doi: 10.1097/JCP.0000000000000408.
Methamphetamine (METH) abuse and dependence present a major global problem. We investigated the efficacy of adding buprenorphine in reducing METH cravings during treatment with the Matrix program.
This was a randomized, double-blind, controlled clinical trial of 40 men between the age of 18 and 40 years who were referred to the addiction treatment center at Noor Hospital from December 2012 to September 2013. All of the selected subjects participated in the Matrix program and were randomly assigned into 2 groups and given either buprenorphine or a placebo. A 4-month intervention program with buprenorphine or a placebo was arranged for each group. Demographic variables of the 2 groups, descriptive indices from the cocaine craving questionnaire-brief (CCQ-Brief), the ratio of urine tests positive for METH, and the frequency of drug complications were regularly evaluated in both groups every 2 weeks and, if not possible, by the third or fourth week. All analyses were performed by SPSS20 using analysis of covariance, χ, and t tests.
The average of indices from the cocaine craving questionnaire-brief score, except the 2 initial measurements, was significantly lower in the intervention group in all measurements (P < 0.05). Apart from weeks 3 and 28, the ratio of positive tests was significantly different in all measurements in both groups (P < 0.05).
Buprenorphine augmentation, in comparison with the placebo, significantly reduced the craving to use METH during treatment with the Matrix program.
甲基苯丙胺（冰毒）滥用和成瘾是一个重大的全球性问题。我们研究了在采用Matrix项目治疗期间添加丁丙诺啡以减少对冰毒的渴望的疗效。
这是一项随机、双盲、对照临床试验，研究对象为2012年12月至2013年9月被转介至努尔医院成瘾治疗中心的40名年龄在18至40岁之间的男性。所有入选受试者均参与Matrix项目，并被随机分为两组，分别给予丁丙诺啡或安慰剂。为每组安排了一个为期4个月的丁丙诺啡或安慰剂干预项目。两组的人口统计学变量、可卡因渴望问卷简版（CCQ-Brief）的描述性指标、冰毒尿检阳性率以及药物并发症的发生频率，每2周定期在两组中进行评估，若无法在第2周评估，则在第3周或第4周评估。所有分析均使用SPSS20通过协方差分析、χ检验和t检验进行。
除最初的两次测量外，干预组在所有测量中可卡因渴望问卷简版评分的各项指标平均值均显著较低（P < 0.05）。除第3周和第28周外，两组在所有测量中的检测阳性率均存在显著差异（P < 0.05）。
与安慰剂相比，在采用Matrix项目治疗期间，添加丁丙诺啡可显著降低对使用冰毒的渴望。
